Spray-Dried Lactobacillus Stems/Cells and the Use of Same Against Helicobacter Pylori
The invention relates to spray-dried Lactobacillus strains and/or Lactobacillus cells (lactic acid bacteria) and to the uses thereof, in particular for pharmaceutical and/or dietary compositions for the treatment and prophylaxis of Helicobacter pylori infections in humans and animals.
1 - 15 . (canceled)
16 . A composition comprising spray-dried Lactobacillus cells for use in the treatment and prophylaxis of Helicobacter pylori infections in humans or animals.
17 . The composition of claim 16 , wherein said spray-dried Lactobacillus cells are essentially present in monomer and/or dimer form.
18 . The composition of claim 16 , wherein:
a) Lactobacillus cells are spray-dried; and
b) spray-dried Lactobacillus cells that are obtained are introduced into a physiologically compatible carrier.
19 . The composition of claim 16 , wherein co-aggregates are formed with Helicobacter pylori in situ after application in the stomach medium.
20 . The composition of claim 19 , wherein the co-aggregates are not smaller than 50 μm, and more particularly are larger than 500 μm.
21 . The composition of claim 16 , wherein the Lactobacillus cells are selected from the group consisting of Lactobacillus lactis, Lactobacillus helveticus, Lactobacillus jensenii, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus amylovorus, Lactobacillus delbrueckii, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus pentosus, Lactobacillus rhamnosus, Lactobacillus curvatus and Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus fructivorans, Lactobacillus hilgardii, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus viridescens, DSM 17646, DSM 17647, DSM 17648, DSM 17649, DSM 17650, DSM 17651, DSM 17652, DSM 17653.
22 . The composition of claim 16 , wherein the Lactobacillus cells are selected from the group consisting of Lactobacillus fermentum, Lactobacillus brevis, Lactobacillus reuteri, Lactobacillus buchneri and Lactobacillus pentosus.
23 . A pharmaceutical or dietary composition comprising the composition of claim 16 and optionally further comprising adjuvants and additives.
24 . The pharmaceutical or dietary composition of claim 23 , in form of food or foodstuff and/or feedstuff for pets and/or farm animals, or in form of dietary supplement.
25 . The composition of claim 16 for eradication therapy of Helicobacter pylori, optionally in combination with further suitable active ingredients.
26 . A pharmaceutical product comprising spray-dried Lactobacillus cells or the composition of claim 16 for use with Helicobacter pylori infections in humans or animals.
27 . A dietary supplement comprising spray-dried Lactobacillus cells or the composition of claim 16 for use with Helicobacter pylori infections in humans or animals.
28 . A method for producing the composition of claim 16 , or a pharmaceutical product or dietary supplement comprising said composition, comprising:
(i) fermenting Lactobacillus cells;
(ii) spray-drying the Lactobacillus cells; and
(iii) mixing the spray-dried Lactobacillus cells with a physiologically compatible carrier,
optionally the Lactobacillus cells are first inoculated and enriched.
29 . A method for the prophylaxis and/or treatment of conditions caused by an infection with Helicobacter pylori in a human or an animal, comprising administering a pharmaceutical or dietary composition comprising spray-dried Lactobacillus cells to a human or an animal in need thereof.
30 . The method of claim 29 , wherein said conditions caused by an infection with Helicobacter pylori are selected from the group consisting of gastrointestinal conditions, gastritis, stomach ulcers, stomach cancer, abdominal discomfort, discomfort of the upper abdomen, gastric heaviness, gastric spasms, stomach pain, pain or pressure in the upper abdomen, burning sensation in the upper abdomen, chronic-recurrent abdominal disorders, permanent feeling of fullness, lack of appetite, fasting pain, bloating, heartburn, diarrhea, irregular bowel movements, indisposition, nausea, sickness and vomiting, food intolerance, malabsorption, upset stomach (functional dyspepsia), gastritis, damage to the mucous membrane, and gastroduodenal ulcer.
31 . An eradication therapy of Helicobacter pylori comprising utilizing spray-dried Lactobacillus cells or the composition of claim 16 , optionally in combination with further suitable active ingredients.
32 . The eradication therapy of claim 31 , wherein said suitable active ingredients are antibiotics.
33 . A pharmaceutical product or dietary supplement for the prophylaxis and/or treatment of conditions caused by infections with Helicobacter pylori, or for use in the eradication therapy of Helicobacter pylori, comprising spray-dried Lactobacillus cells or the composition of claim 16 , optionally in combination with further suitable active ingredients.
34 . The pharmaceutical product or dietary of claim 33 , wherein the conditions caused by infections with Helicobacter pylori are selected from the group consisting of gastrointestinal conditions, gastritis, stomach ulcers, stomach cancer, abdominal discomfort, discomfort of the upper abdomen, gastric heaviness, gastric spasms, stomach pain, pain or pressure in the upper abdomen, burning sensation in the upper abdomen, chronic-recurrent abdominal disorders, permanent feeling of fullness, lack of appetite, fasting pain, bloating, heartburn, diarrhea, irregular bowel movements, indisposition, nausea, sickness and vomiting, food intolerance, malabsorption, upset stomach (functional dyspepsia), gastritis, damage to the mucous membrane, and gastroduodenal ulcer.
35 . The pharmaceutical product or dietary of claim 33 , wherein suitable active ingredients are antibiotics.